Physician profile
John K Boyer
NPI 1912999285
$2,286.95
in general payments reported to CMS, 2019-2025
23 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $305 · 2021: $188 · 2022: $470 · 2023: $321 · 2024: $279 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,068.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $406.77 | 2019-2023 | Amplatzer Talisman |
| Amgen INC. | $382.36 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $278.07 | 2019-2025 | |
| Novo Nordisk INC | $234.14 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $215.52 | 2021-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $110.53 | 2021-2023 | Lifevest |
| Abiomed | $92.49 | 2023-2025 | Impella |
| Boston Scientific Corporation | $78.53 | 2020-2024 | Watchman Access System |
| Pfizer INC. | $71.58 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $66.47 | 2022-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $54.86 | 2019-2022 | |
| Medtronic Vascular, INC. | $39.78 | 2019-2020 | |
| Medtronic, INC. | $39.70 | 2022-2025 | Aurora Ev-Icd Mri Surescan |
| Merck Sharp & Dohme LLC | $32.88 | 2023-2024 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $32.15 | 2023 | Inpefa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $29.41 | 2019-2025 | Evkeeza |
| Astrazeneca Pharmaceuticals LP | $27.45 | 2019-2025 | Wainua |
| Alnylam Pharmaceuticals INC. | $18.16 | 2025 | Amvuttra |
| Atricure, INC. | $18.14 | 2023 | |
| Chiesi USA, INC. | $16.68 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.04 | 2024 | |
| Amarin Pharma, INC. | $13.48 | 2019 | |
| Shockwave Medical, INC | $12.76 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Boyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.